Changeflow GovPing Healthcare & Life Sciences Kumquat Biosciences Heterocycle Patent Granted ...
Routine Rule Added Final

Kumquat Biosciences Heterocycle Patent Granted Apr 21

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO granted patent US12606572B2 to Kumquat Biosciences Inc. on April 21, 2026. The patent covers substituted heterocycle compounds and methods for reducing signaling output of oncogenic proteins. The patent application (19352234) was filed October 7, 2025, and the granted patent contains 20 claims classified under C07D 519/00, A61P 35/00, and A61K 31/553.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The USPTO issued patent US12606572B2 to Kumquat Biosciences Inc. for substituted heterocycle compounds useful in reducing oncogenic protein signaling output. The patent names Pingda Ren, Baogen Wu, Xiaoming Li, Xiaohui He, and Liansheng Li as inventors. The 20-claim patent covers therapeutic applications in oncology.

For pharmaceutical and biotechnology companies, this patent grant establishes IP protection for heterocycle-based therapeutic compositions. Competitors developing similar compounds targeting oncogenic protein pathways may need to design around this patent or seek licensing arrangements with Kumquat Biosciences.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Substituted heterocycles and uses thereof

Grant US12606572B2 Kind: B2 Apr 21, 2026

Assignee

Kumquat Biosciences Inc.

Inventors

Pingda Ren, Baogen Wu, Xiaoming Li, Xiaohui He, Liansheng Li

Abstract

The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic protein.

CPC Classifications

C07D 519/00 A61P 35/00 A61K 31/553

Filing Date

2025-10-07

Application No.

19352234

Claims

20

View original document →

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 21st, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12606572B2

Who this affects

Applies to
Pharmaceutical companies Manufacturers
Industry sector
3254.1 Biotechnology
Activity scope
Patent granting Drug discovery
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!